Hemorai
Hemorai is at the forefront of revolutionizing blood analysis through artificial intelligence, combining advanced machine learning algorithms with traditional hematology to deliver faster, more accurate diagnostic results. The company's mission is to improve healthcare outcomes by making blood analysis more efficient, accurate, and accessible, helping healthcare providers make better decisions faster to enhance patient care.
Industries
Nr. of Employees
small (1-50)
Products
Gen 1 — Benchtop diffuse reflectance spectroscopy prototype
Proof-of-concept benchtop system that validated the use of diffuse reflectance spectroscopy for hemorrhage detection in laboratory settings.
Gen 2 — Portable working prototype with real-time processing
Compact, portable prototype featuring enhanced optical sensors and on-device real-time processing; undergoing clinical validation with academic partners.
Gen 3 — Planned miniaturized commercial wearable
Planned commercial wearable design intended to be miniaturized with wireless connectivity and extended battery life; development slated to begin in 2025 in collaboration with engineering partners.
Gen 1 — Benchtop diffuse reflectance spectroscopy prototype
Proof-of-concept benchtop system that validated the use of diffuse reflectance spectroscopy for hemorrhage detection in laboratory settings.
Gen 2 — Portable working prototype with real-time processing
Compact, portable prototype featuring enhanced optical sensors and on-device real-time processing; undergoing clinical validation with academic partners.
Gen 3 — Planned miniaturized commercial wearable
Planned commercial wearable design intended to be miniaturized with wireless connectivity and extended battery life; development slated to begin in 2025 in collaboration with engineering partners.
Services
Design and execution support for clinical validation studies in collaboration with academic medical centers to evaluate device performance across populations.
Engineering and prototyping services to transition benchtop optical systems to compact, wearable designs with wireless connectivity and extended battery life.
Collaborative research programs with universities and funding agency engagement to develop and validate optical monitoring technologies.
Design and execution support for clinical validation studies in collaboration with academic medical centers to evaluate device performance across populations.
Engineering and prototyping services to transition benchtop optical systems to compact, wearable designs with wireless connectivity and extended battery life.
Collaborative research programs with universities and funding agency engagement to develop and validate optical monitoring technologies.
Expertise Areas
- Wearable medical device development
- Optical spectroscopy and biomedical optics
- Microcirculation and perfusion monitoring
- Non-invasive hemorrhage detection
Key Technologies
- Speckleplethysmography (SPG)
- Laser speckle imaging
- Diffuse reflectance spectroscopy
- Optical spectroscopy
News & Updates
Hemorai has been approved for a prestigious grant from the UMass Center for Advancing Point of Care in Heart, Lung, Blood, and Sleep Diseases (CAPCaT), a member of the NIH Point-of-Care Network (POCTRN). This funding will enable the development of a wearable technology to monitor pregnancy and post-delivery health, focusing on early detection of complications.
Hemorai has been selected as one of the winners of the MeHi Digital Health Sandbox Program, which will enable clinical validation of its wearable technology with UMass Chan Medical School, focusing on efficacy and application, especially in patients with darker skin tones.
Hemorai has been approved for a prestigious grant from the UMass Center for Advancing Point of Care in Heart, Lung, Blood, and Sleep Diseases (CAPCaT), a member of the NIH Point-of-Care Network (POCTRN). This funding will enable the development of a wearable technology to monitor pregnancy and post-delivery health, focusing on early detection of complications.
Hemorai has been selected as one of the winners of the MeHi Digital Health Sandbox Program, which will enable clinical validation of its wearable technology with UMass Chan Medical School, focusing on efficacy and application, especially in patients with darker skin tones.